TABLE 2

Pretreatment predictive factors associated with hepatocarcinogenesis in 1,922 patients with SVR after all-oral DAA regimensb

FactorUnivariate analysisMultivariate analysis
HR95% CIP valueaHR95% CIP valuea
Sex
    Male1
    Female0.520.29–0.960.037
Age (yr)
    <6511
    ≥652.041.05–3.960.0373.590.79–16.30.097
Body mass index (kg/m2)
    <23.01
    ≥23.01.821.00–3.300.050
Aspartate aminotransferase concn (IU/liter)
    <501
    ≥502.521.38–4.610.003
Alanine aminotransferase concn (IU/liter)
    <501
    ≥501.780.98–3.240.059
Platelet count (104/mm3)
    <20.01
    ≥20.00.450.19–1.060.066
Total cholesterol level (mg/dl)
    <1701
    ≥1700.520.28–0.980.042
Low-density lipoprotein cholesterol level (mg/dl)
    <901
    ≥900.230.10–0.560.001
Level of viremia (log IU/ml)
    <6.01
    ≥6.00.560.31–1.010.055
Alpha-fetoprotein concn (μg/liter)
    <51
    ≥53.831.71–8.620.001
WFA+M2BP level (COI)
    <2.511
    ≥2.57.092.59–19.4<0.0013.571.24–10.30.019
HCV core subgroup
    HCV-2a/2b11
    HCV-1b core aa 70 wild3.000.87–10.30.08110.51.28–86.00.029
    HCV-1b core aa 70 mutant4.101.21–13.90.02319.72.51–1550.005
HCV NS5A subgroup
    HCV-2a/2b1
    HCV-1b NS5A aa 93 wild2.460.75–8.120.140
    HCV-1b NS5A aa 93 mutant4.311.17–15.90.029
  • a Significance was determined using the Cox proportional hazard model.

  • b HR, hazard ratio; CI, confidence interval. Only variables that achieved statistical significance or marginal significance on univariate analysis are shown.